Johnson & Johnson MedTech has announced a strategic co-promotion agreement with Pacira BioSciences, Inc. to enhance its Early Intervention portfolio for osteoarthritis of the knee. This collaboration introduces ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), a non-opioid treatment option aimed at alleviating pain associated with osteoarthritis. The partnership aims to advance orthopaedic care by offering non-surgical solutions earlier in the treatment process, addressing the needs of over 30 million affected adults in the United States. The agreement also includes initiatives to increase professional education and patient engagement, focusing on providing effective, longer-lasting pain relief and improving patient outcomes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。